- Conditions
- X-linked Hypophosphatemia
- Interventions
- Placebo, KRN23
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Indianapolis, Indiana • Durham, North Carolina + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2233–2256
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- 552-02
- Drug
- Lead sponsor
- Parion Sciences
- Industry
- Eligibility
- 14 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 15
- States / cities
- San Diego, California • San Francisco, California • Denver, Colorado + 12 more
- Conditions
- Cystic Fibrosis, Liver Disease or Abnormalities, Diabetes, Pancreatic Insufficiency (Exocrine and Endocrine)
- Interventions
- Not listed
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 4 Years to 120 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1988 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Marfan Syndrome
- Interventions
- Exercise Intervention Group, Control Group
- Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polycystic Ovary Syndrome, Obesity, Hyperandrogenism
- Interventions
- Dexamethasone, rhCG
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 7 Years to 18 Years · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2025
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Cystic Fibrosis, Dysbiosis
- Interventions
- Vitamin D3, Placebo vitamin D3, Inulin, Placebo Inulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Sudden Unexplained Death Syndrome, Sudden Unexplained Death in Childhood
- Interventions
- Biospecimin Collection
- Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 11 Months to 100 Years
- Enrollment
- 1,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neonatal Jaundice, Hyperbilirubinemia
- Interventions
- Stanate (TM) [stannsoporfin, tin-mesoporphyrin]
- Drug
- Lead sponsor
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- Industry
- Eligibility
- 12 Hours to 1 Week
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Fanconi Anemia
- Interventions
- metformin HCl
- Drug
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Congenital Heart Defects
- Interventions
- Diagnostic cardiac MRI, Cardiac catheterization
- Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 6 Weeks to 5 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Ataluren
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 2 Years to 7 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 6 more
- Conditions
- Sickle Cell Disease
- Interventions
- haploidentical stem cell transplant, Sirolimus, Alemtuzumab, Pentostatin, Cyclophosphamide, Hydroxyurea, Filgrastim
- Procedure · Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- vorinostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Blood Coagulation Disorders, Inherited, Thrombotic Disorder
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 1 Day to 98 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2028
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Preterm Birth, Pregnancy, Fetal Growth Abnormalities
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2016
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Royal Oak, Michigan
- Conditions
- Cerebral Palsy, Pes Planus
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 4 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Juvenile Idiopathic Arthritis (JIA), Fibromyalgia, Lupus, Scoliosis, Pectus Excavatum, Chronic Pain, Musculoskeletal Pain
- Interventions
- Not applicable- observational study
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 14 Years to 26 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Sickle Cell Disease
- Interventions
- Voice Crisis Alert V2, Electronic educational materials
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 14 Years to 21 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Glucosephosphate Dehydrogenase Deficiency, Hyperbilirubinemia, Hemolytic Disease of Newborn
- Interventions
- tin mesoporphyrin
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 0 Years to 24 Hours
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Sickle Cell Disease
- Interventions
- MGTA-145, Plerixafor
- Biological · Drug
- Lead sponsor
- Ensoma
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Boston, Massachusetts • Memphis, Tennessee
- Conditions
- Colic, Inflammation
- Interventions
- Nutramigen with Enflora, Nutramigen A+
- Dietary Supplement
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 3 Weeks to 3 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Congenital Heart Disease
- Interventions
- Not listed
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Up to 2 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Infant, Premature, Patent Ductus Arteriosus, Infant, Newborn, Diseases, Patent Ductus Arteriosus After Premature Birth
- Interventions
- Active Treatment, Expectant Management
- Other
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 48 Hours to 21 Days
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
- Conditions
- Preterm Infants, Dolichocephaly, Positional Scaphocephaly
- Interventions
- Tortle Midliner
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 23 Weeks to 30 Weeks
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina